HP and Parkinson disease: Exploring interactions of different HP antibodies with dopamine pharmacokinetics, gut microbiota (gut-brain axis), or central neuropathology related to PD (synuclein in brain tissues such as the striatum, substantia nigra, etc.)may help elucidate the underlying mechanisms.